Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients

What Was Tested

The paper reports a study of Glucagon in the context of insulin resistance, prediabetes & type 2 diabetes, published as a randomized controlled trial.

Who Took Part

The abstract describes 4 patients taking part.

The age groups tagged for this paper are middle-aged adults, men only.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Glucagon.

The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.

In the crossover set-up each of the patients took both Glucagon and the comparison in turn, acting as their own control.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Calorimetry, Indirect, Fatty Acids, Nonesterified, Glucagon, Glucagon-Like Peptide 1, Glucose Clamp Technique and Glucose Tolerance Test.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon in 4 patients in people with insulin resistance, prediabetes & type 2 diabetes.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2012 (Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association), a journal based in Germany.

More context: the Glucagon compound page, Insulin resistance, prediabetes & type 2 diabetes research.